Patents by Inventor Francois Gaudet
Francois Gaudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101697Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.Type: ApplicationFiled: June 12, 2023Publication date: March 28, 2024Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
-
Patent number: 11884722Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: GrantFiled: January 20, 2023Date of Patent: January 30, 2024Assignee: JANSSEN BIOTECH, INC.Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
-
Publication number: 20230322924Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.Type: ApplicationFiled: March 8, 2023Publication date: October 12, 2023Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan Mcdaid, Jennifer Nemeth-Seay
-
Publication number: 20230227548Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: ApplicationFiled: January 20, 2023Publication date: July 20, 2023Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoido Luistro, Diana Chin
-
Patent number: 11685777Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: GrantFiled: February 3, 2020Date of Patent: June 27, 2023Assignee: Janssen Pharmaceutica NVInventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
-
Publication number: 20230084967Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: ApplicationFiled: February 3, 2020Publication date: March 16, 2023Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Yingzhe Li, Leopoldo Luistro, Diana Chin
-
Patent number: 11603405Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.Type: GrantFiled: May 21, 2019Date of Patent: March 14, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan McDaid, Jennifer Nemeth-Seay
-
Patent number: 11466082Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.Type: GrantFiled: May 21, 2019Date of Patent: October 11, 2022Assignee: JANSSEN BIOTECH, INC.Inventors: Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
-
Publication number: 20210363252Abstract: Disclosed herein is a pharmaceutical composition comprising a T cell redirect therapeutic and a VLA-4 adhesion pathway inhibitor, and uses thereof for killing cancer cells.Type: ApplicationFiled: May 18, 2021Publication date: November 25, 2021Inventors: Priyanka Nair-Gupta, François Gaudet
-
Patent number: 10844122Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.Type: GrantFiled: May 6, 2016Date of Patent: November 24, 2020Assignee: Janssen Biotech, Inc.Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
-
Publication number: 20200231686Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.Type: ApplicationFiled: January 15, 2020Publication date: July 23, 2020Inventors: Ricardo Attar, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani
-
Publication number: 20200190205Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.Type: ApplicationFiled: May 15, 2019Publication date: June 18, 2020Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
-
Patent number: 10562968Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: GrantFiled: July 20, 2017Date of Patent: February 18, 2020Assignee: Janssen Pharmaceutica NVInventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L Luistro, III, Diana Chin
-
Publication number: 20200048349Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.Type: ApplicationFiled: May 21, 2019Publication date: February 13, 2020Inventors: Francois GAUDET, Jill GILES-KOMAR, Bradley HEIDRICH, Chichi HUANG, Colleen KANE, Ronan MCDAID, Jennifer NEMETH-SEAY
-
Publication number: 20190382481Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.Type: ApplicationFiled: May 21, 2019Publication date: December 19, 2019Inventors: Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
-
Publication number: 20190352421Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.Type: ApplicationFiled: May 15, 2019Publication date: November 21, 2019Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
-
Publication number: 20190270826Abstract: Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multi specific antibodies against IL1RAP and CD3 described herein.Type: ApplicationFiled: March 20, 2019Publication date: September 5, 2019Applicant: JANSSEN PHARMACEUTICA NVInventors: Bradley J. Heidrich, Jennifer F. Nemeth, Walter K. Nishioka, JR., Thai Dinh, Rosa Maria Fernandes Cardoso, Ricardo Marcos Attar, Francois Gaudet, Mark E. Salvati
-
Patent number: 10072088Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.Type: GrantFiled: August 16, 2016Date of Patent: September 11, 2018Assignee: Janssen Pharmaceutica, NVInventors: Kodandaram Pillarisetti, Eric Thomas Baldwin, Gordon D. Powers, Rosa Maria Fernandes Cardoso, Ricardo Attar, Francois Gaudet
-
Publication number: 20180037651Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: ApplicationFiled: July 20, 2017Publication date: February 8, 2018Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
-
Patent number: 9850310Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.Type: GrantFiled: September 3, 2015Date of Patent: December 26, 2017Assignee: Janssen Pharmaceutica NVInventors: Francois Gaudet, Jennifer F. Nemeth, Ricardo Attar, Benjamin C. Harman, Yingzhe Li, Jinquan Luo, Ronan McDaid, Steven C. Pomerantz, Susan H. Tam, Alexey Teplyakov, John Wheeler, Sheng-Jiun Wu